Pharmacological Chaperones Stabilize Recombinant Proteins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Recombinant protein production is hindered by the instability of proteins in the endoplasmic reticulum, leading to premature degradation and reduced yields, particularly for complex proteins like cystic fibrosis transmembrane conductance regulator and clotting factors, which suffer from folding inefficiencies and ER stress.
Innovation Solution
The use of pharmacological chaperones, such as 1-deoxynojirimycin, 1-deoxygalactonojirimycin, and isofagomine, which bind to recombinant proteins to stabilize them, enhance export from the endoplasmic reticulum, increase secretion, and maintain stability during purification and storage, thereby reducing ER stress and proteolytic digestion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If recombinant proteins are over-expressed in mammalian cell culture systems, then production level increases, but protein stability decreases leading to premature degradation and reduced yields
Solution Approach 1:
Pharmacological chaperones act as intermediary molecules that bind to recombinant proteins in the ER, stabilizing their conformation and preventing degradation. This mediator approach allows high-level expression to be maintained while protein stability is preserved through the chaperone-protein complex formation.
Solution Approach 2:
The invention changes the physical-chemical parameters of the protein by introducing pharmacological chaperones that alter the protein's conformational stability, thermal resistance, and pH tolerance. This parameter modification enables proteins to maintain stability under over-expression conditions that would otherwise lead to degradation.
2Productivity
If complex proteins are produced in high quantities, then yield increases, but ER stress increases leading to cellular toxicity and reduced production efficiency
Solution Approach 1:
Pharmacological chaperones are introduced to perform preliminary protective action on recombinant proteins before they can cause ER stress. By stabilizing proteins in the ER lumen, the chaperones prevent the accumulation of misfolded proteins that would otherwise trigger ER stress responses and cellular toxicity.
Solution Approach 2:
The pharmacological chaperone serves as a mediator between the ER quality control system and the recombinant protein, facilitating proper folding and export while preventing the activation of stress pathways. This intermediary function allows high-yield production without the harmful effects of ER stress.
3Adaptability or versatility
If mutant proteins are expressed, then therapeutic potential increases, but folding efficiency decreases causing ER retention and degradation
Solution Approach 1:
Pharmacological chaperones act as specific intermediaries that bind to mutant proteins with altered conformations, stabilizing them in a foldable state. This mediator approach enables mutant proteins that would otherwise be retained and degraded in the ER to achieve proper folding and be successfully expressed for therapeutic applications.
Solution Approach 2:
The pharmacological chaperone performs preliminary stabilization of the mutant protein conformation during synthesis, preventing premature degradation and enabling the protein to complete folding and export processes that would otherwise fail due to the mutant's inherent folding inefficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The binding of pharmacological chaperones significantly increases the thermal stability and secretion of recombinant proteins, reduces premature degradation, and enhances the yield and stability during storage, effectively addressing the challenges of protein instability and ER stress in recombinant protein production.
Implementation Method 1
the binding of a pharmacological chaperone to a recombinant protein expressed by a cell can stabilize the protein
Implementation Method 2
increase export of the protein out of the cell's endoplasmic reticulum
Implementation Method 3
increase secretion of the protein by the cell
Implementation Method 4
The binding of pharmacological chaperones significantly increases the thermal stability and secretion of recombinant proteins
Data Source
AI summary
The present invention provides methods for improving the production of recombinant proteins through the use of pharmacological chaperones for the recombinant proteins. As exemplified by the present invention, the binding of a pharmacological chaperone to a recombinant protein expressed by a cell can stabilize the protein and increase export of the protein out of the cell's endoplasmic reticulum, and increase secretion of the protein by the cell.